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atedwith TVR/PR relative to PR alone, resulting in an ICER of £14,230 for treatment-
naïve patients and £9,440 across the overall treatment-experienced patients. The
ICER of the prior relapse, prior partial responder and prior null-responder sub-
populations, were £5,363, £10,558 and £27,725, respectively. CONCLUSIONS: The
introduction of telaprevir to current standard of care for HCV genotype 1 patients is
clinically more efficacious than PR alone and cost-effective for both treatment
naïve and experienced patients at the £20,000 and £30,000 willingness-to-pay
thresholds.
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OBJECTIVES: Streptococcus pneumoniae causes significant morbidity and mortality
worldwide in both children and adults. The aim of this analysis is to evaluate the
cost-effectiveness of vaccinating the Colombia population over 50 years with 13-
valent pneumococcal conjugated vaccine (PCV 13) vs. 23-valent pneumococcal
polysaccharide vaccine (PPSV23) to estimate the clinical benefits and associated
costs from the third-party payer perspective in Colombia. METHODS: A Markov
model simulating vaccination and outcomes was adapted to Colombian settings,
using a timehorizon of 5 years (5% annual discount rate). Comparatorswere PCV13,
PPSV23 (70% coverage) and no vaccination; revaccinationwith PPSV23 after 5 years
in adults at high risk according to CDC criteria was considered. Probabilities and
costs were extracted from a literature review, the incidence of diseases was re-
trieved from local database and costs are presented in 2011 US$. Effectiveness
measures were the number of pneumococcal diseases and deaths prevented, as
well as life years (LY) saved. Probabilistic sensitivity analyses were developed.
RESULTS:Over a 5 year period, vaccinatingwith PCV13 compared to PPSV23 and no
vaccination prevents 3,277 and 15,930 cases of invasive pneumococcal disease;
156,722 and 157,893 cases of hospitalized pneumonia; 11,383 and 12,358 non-com-
plicated pneumonia and 6,613 and 7,691 deaths respectively, PCV13 saves 13,347
LY’s compared to PPSV23 and 18,321 LY’s compared to no vaccination. Total ex-
pected savings (considering vaccination costs  medical costs and expressed in
US$ millions) for PCV13 was US$ 113.7M compared to PPSV23 and US$ 74.9M com-
pared to no vaccination (total expected costs: US$ 1,462.5M; US$ 1,576.2M and US$
1,537.4M respectively). CONCLUSIONS: Vaccinating adults over 50 years with
PCV13 in Colombia is a cost-saving alternative in comparison to PPSV23 and to no
vaccination (US$ 13 and US$9 per patient, respectively). These savings could posi-
tive impact the burden of disease and study findings could support the decision-
making process in favor of PCV13.
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OBJECTIVES: Telaprevir and Boceprevir were approved in May 2011 for the treat-
ment of chronic hepatitis C in combination with the standard therapy of peginter-
feron-ribavirin. The objective of this study was to compare the cost-effectiveness
of the addition of Telaprevir or Boceprevir to the standard therapy versus the
standard therapy alone for the treatment of previously untreated chronic hepatitis
C genotype 1 virus infection. METHODS: A Markov model was constructed using
TreeAge Pro version 2011. Six Markov states were identified based on the clinical
progression of chronic hepatitis C. The model was run over a 28 year time horizon
with 1 year cycle lengths. Clinical inputs (treatment response rates and probabili-
ties of adverse drug reactions) were obtained from two published phase III clinical
trials comparing the combination of Telaprevir or Boceprevir with the standard
therapy versus treating patients with standard therapy alone. Treatment costs,
transition probabilities, and health state utilities were obtained from the Medical
Expenditure Panel Survey data and other published literature. The primary out-
come measure used was quality adjusted life years (QALYs). Future costs and out-
comes were discounted at 5%. The analysis was conducted from the payer’s per-
spective. Multiple one-way sensitivity analyses were conducted by varying drug
costs, treatment response rates and the discount rate. RESULTS: The incremental
cost effectiveness ratio (ICER) for adding Telaprevir to the standard therapy versus
the standard therapy alone was $17,974.93/QALY gained while the ICER for adding
Boceprevir to the standard therapy versus the standard therapy alone was
$9,476.61/QALY gained. CONCLUSIONS: Based on the results, adding Boceprevir or
Telaprevir to the standard therapy was found to be cost-effective as compared to
treating patients with standard therapy alone. Furthermore, adding Boceprevir to
the standard therapy was found to be more cost-effective as compared to adding
Telaprevir.
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OBJECTIVES: Influenza can cause significant mortality, morbidity and economic
burden in a population, with vulnerable groups being disproportionally affected.
Vaccinating healthy children to produce herd effect has been proposed as a strat-
egy to protect vulnerable groups. This strategy was investigated in the Hutterite
Influenza Prevention Study, a clustered RCT comparing communities with or with-
out childhood influenza immunization programs. There will be costs associated
with vaccinating all healthy children in a community; therefore there may be a
trade-off between these costs and the benefits of avoiding influenza cases. The
study objective is to evaluate the cost-effectiveness of immunizing healthy chil-
dren to create herd immunity within entire communities. METHODS: Data from
the trial were used for effect inputs. Resource utilization was recorded during the
trial and cost data were collected from third party payer, literature and internet
sources. A two-stage bootstrap (TSB) with shrinkage correction was used to esti-
mate costs and effects (influenza cases avoided).The base case incremental cost
effectiveness ratio (ICER) and sample uncertainty around this estimate were cal-
culated from the TSB results. RESULTS: Mean costs per patient for the treatment
and control armswere $51.32 and $33.26 respectively (difference $18.06). Themean
number of influenza cases was estimated to be 0.05 for the treatment arm and 0.28
for the control arm (difference 0.23). ICER was $80.36 (dominates, $2,263.82) per
case of influenza averted. The probability of the treatment arm being cost-effective
was 90% at a willingness-to-pay of $1000 per case of influenza prevented. One way
sensitivity analysis showed results to be robust. CONCLUSIONS: Immunizing
healthy children for influenza is more costly, yet more effective than no influenza
immunization in preventing cases of influenza in the entire sample. At a cost of
$80.36 to prevent a case of influenza, immunizing healthy children to protect all
community members may be considered cost-effective.
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OBJECTIVES: Candidemia accounts for 50 to 70% of the manifestations of invasive
candidiasis (IC) and in Colombia Candida albicans is the most frequently isolated
specie in IC (43.6%). The emergence of new antifungal agents such as echinocan-
dins family therapy provides great opportunities to manage candidemia, with fa-
vorable safety profile and broad spectrum fungicide. The purpose of this study was
to evaluate the cost-effectiveness of multiple treatments for non-neutropenic crit-
ically ill patients hospitalized in an intensive care unit (ICU) with highly suspected
or confirmed IC comparing amphotericin B, anidulafungin, and caspofungin from
the third-party payer perspective in Colombia. METHODS: A decision-tree model
was developed to assess the cost-effectiveness of empiric treatments for IC, using
a time horizon of 14 weeks. Comparators were: amphotericin B (0,6mg/kg/day),
anidulafungin (100mg/day), and caspofungin (50mg/day). Effectiveness data and
adverse event rates for comparators were obtained through a Colombian meta-
analysis using the results from a systematic review. Direct medical costs were
gathered from the Colombian Tariff Manual (SOAT) and acquisition costs were
retrieved from the 2011 SISMED report from Colombia. All data were validated
through a ColombianDelphi Panel who estimated schemes for IC treatment (drugs,
hospitalization, and medical manage associated with adverse events: such as
nephrotoxicity and hypokalemia). Effectiveness was expressed through life years
gained (LYG). Incremental cost per life year gained (ICER) and sensitivity analyses
were performed to test model robustness. RESULTS: Anidulafungin showed to be
cost-saving vs. caspofungin reducing overall costs (2011 US$) by US$924.80 and
gaining additional 0.47 LYG. Likewise, anidulafungin was highly cost-effective
compared to amphotericin B (ICER $1153.67/LYG); due to rates reduction of side
effect events: anidulafungin 24.4%, caspofungin 42.1% and amprothericin B 75.2%
and its associated costs. CONCLUSIONS: In Colombia, anidulafungin is the most
cost effective option for the treatment of IC in critically ill patients hospitalized at
ICU.
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OBJECTIVES: Complicated intra-abdominal infections are a public health problem
in terms of burden of illness. The purpose of this studywas to develop an economic
model based in Mexican Institute of Social Security (IMSS) resource payments in
order to evaluate the cost-effectiveness of tigecicline /Im-Cl and tigecicline/Pi-Tz vs
Cef-Met/Im-Cl; Cef-Met/Pi-Tz; ertapenem/Im-Cl and ertapenem/Pi-Tz in the treat-
ment of adults with complicated intra-abdominal infections acquired in the
community. METHODS: In a decision-tree model all patients receive first-line
treatment in hospital floor, if they fail then receive second-line treatment in ICU
The combinations were of tigecicline (100mg/day), ceftriaxone/metronidazole (2g/
1.5g/day) and ertapenem (2g/day) with imipenem/cilastatin or piperaciclin/tazo-
bactam to evaluate the cost-effectiveness of tigecicline in the treatment of compli-
cated intra-abdominal infections. The analysis time horizon was 30 days and the
currency used was US dollars. The effectiveness measure was the percentage of
clinical success that was obtained from clinical trials published in the literature
and adjusted for bacterial resistance by conditional probabilitiesmethod. Resource
use and costs were obtained from an expert panel survey and IMSS published data,
respectively. Themodel estimated cost per patient and incremental cost-effective-
ness ratios (ICER). Costs (USD 2011) and effectiveness do not were discounted.
Probabilistic sensitivity analysis was performed using Monte Carlo simulation sec-
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